It's not manipulation. The markets pretty much ignore research in mouse models regardless of how promising it may seem. They know the long odds of positive mouse data translating into an FDA approved therapy in addition to how long it would take. Right now for Imetelstat it's all about the blood.
When they launch into a registration trial after these first 5 patients they will need plenty of cash. I'm certain there will not be an acquisition when there are several stem cell companies they could license the technology from.
"I like Stem's technology" What do you like about it? Their trials to date have not shown any significant signs of efficacy. I like stem cell technology but I don't see much of value with StemCells.
You need some help captain. If everything that appears on this message board is not real then why do you continue to haunt this message board?
Based on your Mayo experience. TIA
Thanks editroid2. You have provided a lot of legitimate commentary here in the past and appreciate it.
I agree. I don't think Chip has any intention of acquiring a pipeline. It's just posturing for a good price when the buyout eventually happens.
There is also additional license potential for Geron as a shell company in licensing the Oligonucleotide IP that looks very promising.
Others have also stated that ALS patients that have major surgery decline more rapidly as a result of the procedure. Therefore, if they were non-responder then their ALS could be worsened. The key is to identify the responders
With 39 sites and counting it does appear it will become a registry study. Only treating 3 or 4 patients per site wouldn't make sense in many ways.
You obviously are unaware of the impressive results they have already reported in the Lancet. Message boards are filled with people making comments about something for which they have little or no knowledge.